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Abstract
Aims Hyponatraemia is an electrolyte disorder that occurs in advanced congestive heart failure (HF) and worsens prognosis.
We explored the usefulness of tolvaptan, which has shown promising results in the treatment of this condition.
Methods and results This study is based on a retrospective national registry (2011–15) of patients hospitalized with refrac-
tory HF and hyponatraemia who agreed to receive tolvaptan when standard treatment was ineffective. The benefit of
tolvaptan was analysed according to the following criteria: normalization ([Na+] ≥ 135 mmol/L) or increased sodium levels
[Na+] ≥ 4 mEq/L on completion of treatment, and increase in urine output by 300 or 500 mL at 48 h. Factors associated with
tolvaptan benefit were explored. A total of 241 patients were included, 53.9% of whom had ejection fraction <40%. All
patients received concomitant loop diuretics. Initial tolvaptan dose was 17.2  6.1 mg, and end dose was 26.4  23.2 mg
(duration 7.8 8.6 days). Serum sodium concentrations increased significantly at 24–48 h, from 126.5 6.2 mEq/L at baseline
to 134.1 6.1 mEq/L at the end of treatment (P< 0.0001). Weight fell by ~5 kg before discharge (P< 0.0001) and urine output
increased 1.3-fold (P < 0.0001). Normal sodium levels and/or increases of 500 mL in urine output were achieved by 90.8% of
patients (35.7% achieved both) and 94.8% increased to [Na+] ≥ 4 mEq/L and/or +300 mL in urine output (54.4% both).
Conclusions An increase in sodium levels and/or improvement in urine output was observed in patients admitted for HF and
refractory hyponatraemia under tolvaptan treatment. Tolvaptan may be useful in this setting, in which no effective proven
alternatives are available.
Keywords Hyponatraemia; Congestive heart failure; Diuresis; Tolvaptan; Vasopressin type 2 receptors
Received: 24 May 2016; Revised: 14 September 2016; Accepted: 2 November 2016
*Correspondence to: Antonio Pose Reino, Hospital de Conxo, Complexo Hospitalario Universitario de Santiago de Compostela, Rúa Ramón Baltar, s/n. 15706 Santiago de
Compostela, La Coruña, Spain. Tel. +34 981 95 10 00. Email: antonioposereino@gmail.com
Introduction
The main physiopathological consequence of heart failure
(HF) is sodium and water retention, which causes
venopulmonary congestion.1 Diuretics constitute the thera-
peutic mainstay in this setting.1,2 Patients with advanced HF
often have hyponatraemia, caused by increased vasopressin
concentrations or by overexcretion of sodium, if loop
diuretics are used excessively or in combination with
thiazides.3,4 Moreover, resistance to diuretics is encountered
relatively frequently, and has been reported in 10–30% of de-
compensated patients.5,6 Resistance to diuretics is defined as
persistent oedema despite adequate diuretic treatment and
restricted salt intake. In practice, it can be suspected in a
patient with a weight loss of <0.5–1 kg/day or urine output
<500 mL/day, despite diuretic treatment. Published
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guidelines vary widely in their recommendations on the diag-
nosis and management of hyponatraemia,7–10 particularly
with regard to hypervolemic hyponatraemia associated with
HF. Some guidelines propose the use of the vasopressin
receptor antagonists, such as tolvaptan, if other treatment
is ineffective.10
Tolvaptan competitively inhibits vasopressin type 2 (V2)
receptors in the collecting duct of the kidney,9–11 effectively
reducing water absorption. This leads to more dilute urine
and an increase in intravascular sodium levels. The SALT11
and SALTWATER12 trials showed that treatment with
tolvaptan increased serum sodium concentration in patients
with hyponatraemia (serum sodium concentration
[Na+] < 135 mEq/L) caused by different physiopathological
and etiological mechanisms, including HF. Moreover, this
drug has a good safety profile. A subanalysis of the EVEREST
trial, which included patients with decompensated HF and re-
duced left ventricular function, found that tolvaptan reduced
the morbidity and mortality of patients with serum
[Na+] < 130 mEq/L.13,14 Furthermore, a placebo-controlled
trial showed that hospitalized patients with HF who received
tolvaptan in addition to the standard intravenous diuretic
treatment for 7 days lost more weight and their congestive
symptoms improved more than in the group who received
conventional diuretics only.15 However, tolvaptan is only ap-
proved in Europe for the treatment of the syndrome of inap-
propriate antidiuretic hormone secretion (SIADH), while in
the US, one of the approved indications is hyponatraemia in
HF patients.10 In fact, the only European clinical practice
guideline for hyponatraemia is positioned against the use of
vaptans in this condition,16 in contrast to the American guide-
line, and contrary to current evidence.
In view of these findings, the aim of this study was to de-
termine the outcomes in patients who received tolvaptan in
addition to added to standard diuretic treatment in clinical
practice, in terms of resolution of hyponatraemia and im-
provement of urine output in hyponatraemic patients with
refractory congestive heart failure (HF) admitted to Spanish
hospitals.
Methods
Patients and data source
We performed a retrospective analysis of patients aged 18 or
older admitted to several Spanish hospitals with refractory,
hyponatraemic HF, who received tolvaptan as inpatients, af-
ter the failure of other treatments with unconfirmed efficacy.
This treatment was administered after tolvaptan was ap-
proved by the EMA for other therapeutic indications in
2011. Diuretic-refractoriness was clinically defined as persis-
tent oedema despite adequate diuretic treatment and
restricted salt intake. Hyponatraemia was not an inclusion
criterion, but fewer than 10% of study patients had normal
serum sodium concentrations at the beginning of treatment.
This was a national registry conducted with the collabora-
tion of the Spanish Society of Internal Medicine (SEMI) and
the Spanish Society of Cardiology (SEC) in eight hospitals dis-
tributed throughout Spain. The database was designed by
representatives from SEMI and SEC, and was regularly
audited to ensure data quality and integrity. The data in-
cluded in this registry are fully anonymous, and data confi-
dentiality is ensured in accordance with the Spanish
Personal Data Protection Act 15/1999, 13 December 1999.
All patients gave consent and were treated according to clin-
ical practice guidelines, and this treatment was in most cases
included in a protocol approved by the Pharmacy Commis-
sion of the participating hospitals. The decisions of the spe-
cialist regarding patient treatment and management were
not influenced in any way, and the management of the partic-
ipating hospitals was informed and authorized the registry
project. Patients with incomplete data were excluded.
Variables
The SEMI-SEC database collects a total of 63 study variables.
These include patient clinical and demographic data (sex, age,
HF aetiology, and drug treatments), details of diuretic treat-
ment before tolvaptan (drugs, dose, duration), tolvaptan
treatment data (initial and final dose and days of treatment),
concomitant diuretic treatment data (drugs and doses), out-
come variables related with the effect of tolvaptan, including
baseline and post-treatment laboratory results (electrolytes),
kidney function parameters (urine output, glomerular filtra-
tion rate according to the Modification of Diet in Renal Dis-
ease [MDRD] Study equation,17 and weight) and follow-up
data (days of treatment, time to normal serum sodium con-
centrations,18 admission to intensive care unit, hospitaliza-
tions, death and cause, etc.).
Evaluation of the outcomes with tolvaptan and
standard diuretic treatment
The criteria used to evaluate the outcomes were final values or
changes in serum sodium and increased urine output, com-
bined in four different premises reflecting benefit. For serum
sodium concentration, benefit was classified as a final sodium
value of ≥135mEq/L or an increase from baseline at the end of
treatment (Δ [Na+]) ≥ 4 mEq/L. These thresholds were
established on the basis of a previously published
hyponatraemia management algorithm, which defines normal
serum sodium as [Na+] ≥ 135 mmol/L, and an appropriate
response to treatment as an increase of 5–10 mEq/L.18
However, taking into account that response to treatment in
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HF is somewhat lower than that expected in other diseases
(due to the multiple mechanisms involved in the physiopa-
thology of the disease), we agreed, for the purposes of this
study, to consider an increase of 4 mEq/L as indicative of
response. With regard to urine output, two thresholds of
increase, 300 or 500 mL, 24–48 h after starting treatment
(Δ urine output), were selected as representative of the
increase in urine output which defines resistance to diuretic
treatment in clinical practice. Using these criteria, we
established four premises reflecting benefit as follows: (i)
final [Na+] ≥ 135 mEq/L, Δ urine output = +500 mL; (ii) Δ
[Na+] ≥ 4 mEq/L, Δ urine output = +500 mL; (iii)
final [Na+] ≥ 135 mEq/L, Δ urine output = +300 mL; and
(iv) Δ [Na+] ≥ 4 mEq/L, Δ urine output = +300 mL. For each
premise, four categories of benefit were determined,
depending on whether one or the other, both or neither
criterion were met.
Statistical analysis
A descriptive analysis was made of all variables. Continuous
variables were expressed as mean and standard deviation
(SD) and qualitative variables as frequencies and percentages.
Comparisons between initial and final values of quantitative
variables were made using the Student t-test for paired sam-
ples, if the distribution of the variable was normal, and the
Wilcoxon test if variables were not normally distributed.
Variables determined at intermediate time points (24 h and
48h)were analysed usingANCOVAmethods for repeatedmea-
surements if distribution was normal, or if otherwise, using the
Friedman test (serum sodium concentration and urine output).
A multinomial logistic regression was used to determine
the relationship of each of the above-mentioned premises
of benefit with certain explanatory variables: sex, age, dia-
stolic blood pressure, days of treatment (classified as
T < 2 days; T = 2–10 days; T > 10 days), final blood potas-
sium, and final glomerular filtration rate using the MDRD
equation. Other variables which did not reach significance
on a previous bivariate analysis, those with too high a propor-
tion of missing data, and those not considered of clinical in-
terest were excluded from this analysis. The reference level
within each premise was that which met both criteria. The
analysis was performed in the R environment.
Results
Baseline clinical characteristics and diuretic
treatments
In total, 241 patients were included. Mean age was
67.5  14.0 years and 58.5% were men. Patient demographic
and clinical characteristics and HF aetiology are summarized
in Table 1.
Almost all patients were receiving loop diuretics before ad-
mission, and more than 60% were receiving mineralocorti-
coid receptor antagonists (MRA). These treatments were
generally maintained after starting treatment with tolvaptan
(Figure 1A). The most common therapeutic strategy before
the introduction of tolvaptan was a combination of loop di-
uretics and MRA (46.4%), and this continued to be the most
frequently used combination during tolvaptan administration
(39.0%) (Figure 1B).
Characteristics of treatment with tolvaptan and
effects of overall treatment
Mean initial dose of tolvaptan was 17.2  6.1 mg, which by
the end of treatment had increased to 26.4  23.2 mg. Mean
treatment duration was 7.8  8.6 days (19.9% <2 days,
55.1% 2–10 days, and 25.0% >10 days; up to a maximum
of 40 days). In general, patients who achieved normal serum
sodium concentrations ([Na+] ≥ 135 mEq/L) did so over a
mean period of 4.3  3.9 days, although 113 (47%) had not
achieved normal levels at completion of treatment. Mean
time to hospital discharge was 13.1  11.9 days.
Figure 2 shows the effect of treatment on serum sodium,
weight and urine output, at the start and end of treatment.
A significant increase in serum sodium levels was observed,
from 126.5  6.2 mEq/L at baseline to 134.1  6.1 mEq/L
at the end of treatment (P < 0.0001). Moreover, the increase
in serum sodium levels was already significant 24 h and 48 h
after starting treatment (P < 0.0001). Mean weight had
Table 1 General patient characteristics
n = 241 Mean  SD n (%)
Age (years) 67.5  14.0
Sex (men) 141 (58.5)




Arterial hypertension 25 (10.5)
Ischaemic heart disease 72 (30.4)
Valvular disease 56 (26.6)
Pulmonary hypertension 9 (3.8)
Other 31 (13.1)
Heart failure parameters (n = 232)
Ejection fraction (%) 41.5  18.7
Ejection fraction ≤40% 125 (53.9)
Ejection fraction >40% 107 (46.1)
Systolic blood pressure (mmHg) 110.8  19.6
Diastolic blood pressure (mmHg) 62.7  9.8
Serum sodium
Baseline [Na+] (mEq/L) 126.5  6.2
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reduced by approximately 5 kg at the time of hospital dis-
charge (P < 0.0001) and final urine output increased 1.3-fold
from baseline (P < 0.0001). Table 2 shows that plasma osmo-
larity also increased significantly. No significant changes were
detected in glomerular filtration rate, blood creatinine or
potassium levels.
Mortality during admission was 20.7%, the main cause be-
ing HF (72.3%) followed by infections in 14.9% of cases, and
other causes in 12.8%. A total of 22.4% of patients were
readmitted within 30 days after discharge.
Premises of treatment benefit
Four efficacy premises were determined, based on final and
initial sodium levels and changes in urine output in the first
48 h after starting treatment. Table 3 (first column) summa-
rizes the percentage of patients who met the specific criteria
of each premise. For the first premise (final [Na+] ≥ 135 mEq/L
and Δ urine output = 500 mL), 90.8% of patients experienced
one or other of the changes considered beneficial, and 35.7%
met both conditions. The proportion of patients who
achieved either of the benefit criteria of premise 2 (Δ
[Na+] ≥ 4 mEq/L and Δ urine output = 500 mL) was 79.5%;
50.7% met both criteria. In premise 3, tolvaptan treatment
was beneficial in 92.7% who had final [Na+] ≥ 135 mEq/L or
Δ urine output = 300 mL or both at the end of treatment
(38.6% met both criteria). Finally, 94.9% of patients showed
a benefit according to the criteria of premise 4; 54.4% met
both criteria (Δ [Na+] ≥ 4 mEq/L and Δ urine
output = 300 mL).
Analysis of factors associated with treatment
benefit
Reduction in blood potassium and increased glomerular fil-
tration rate at the end of treatment were found to be directly
associated with normalization of serum sodium levels; and
final glomerular filtration rate was associated with increased
Figure 2 Comparison of serum sodium values (approximate 1:1 ratio of
1 mEq/L to 1 mmol/L), weight and urine output between start and end
of tolvaptan treatment. Differences were significant for the 3 variables.
Urine output was compared using the Friedman test (P < 0.0001 be-
tween time points; P = 0.900 between 24 and 48 h). Weight and serum
sodium levels were compared using ANOVA for repeated measurements
(P < 0.0001, also between all).
Table 2 Comparison of laboratory and clinical parameters since
the start of treatment with tolvaptan
Mean  SD P-value
Blood creatinine (mg/dL)
Baseline 1.61  0.96 0.44a
End of treatment 1.58  0.89
Blood potassium (mEq/L)
Baseline 4.31  0.71 0.39b
End of treatment 4.27  0.75
Plasma osmolarityc (mOsm/L)
Baseline 272.9  19.6 0.0001b
End of treatment 292.1  19.8
Glomerular filtration rate (MDRD,
mL/min/1.73m2)
Baseline 47.7  27.8 0.42a
End of treatment 49.3  31.3
aWilcoxon test.
bStudentˈs t-test for paired samples.
cNormal plasma osmolarity 280–295 mOsm/kg.
Figure 1 Patientsˈ baseline treatment: (A) frequency of diuretic treat-
ments and (B) most commonly used treatment combinations. ACE inhib-
itors, angiotensin converting enzyme inhibitors; ARBs, angiotensin II
receptor blockers; L-diuretics, loop diuretics; MRA, mineralocorticoid re-
ceptor antagonists.
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urine output, although these parameters varied depending
on the combination of premises (Table 3). Days of treatment
were associated with an increase of 4 mEq/L, suggesting that
this threshold is easier to achieve with longer treatments. In
premise 4, a significant association was found between dia-
stolic blood pressure and a 300 mL increase in urine output
at 24–48 h, and also when urine output was combined with
an increase of sodium in blood. No other variables showed
a significant association with benefit.
Discussion
Our study sample, retrieved from the registry conducted in
Spanish hospitals is, to our knowledge, the largest series in
the literature on the use of tolvaptan in clinical practice in
the treatment of hyponatraemia in patients hospitalized for
acute HF. Hyponatraemia is a condition commonly associated
with advanced HF, and is a prognostic marker of morbidity
and mortality.3,19,20 Management of patients with HF and
hyponatraemia is problematic,21 since water restriction is dif-
ficult to achieve. Moreover, this approach is largely ineffec-
tive, and outcomes are dismal.3,22 Loop diuretics used to
treat oedema are associated with the production of isotonic
urine and do not help to increase serum sodium.3,4,23 Furose-
mide has a aquaretic effect and does contribute to increasing
serum sodium, due to its effect on the renal medulla, but
only in situations in which urinary osmolality is
>350 mOsm/kg.18
This study offers real-world data on the usefulness of
tolvaptan, administered concomitantly with standard diuretic
treatment, and shows that this drug contributes to increasing
serum sodium levels and for increasing urine output in hospi-
talized HF patients, with no significant effects on renal func-
tion. It is interesting to note that over 50% of patients
achieved normal serum sodium at the end of tolvaptan treat-
ment administered in combination with standard diuretic
drugs, and almost 80% experienced an increase in serum so-
dium of at least 4 mEq/L in the first 48 h. Moreover, more
than half of the patients experienced an increase in urine out-
put of over 500 mL.
The combination of diuretic treatment and tolvaptan was
useful in 91% of patients who met the most demanding of
the proposed premises of benefit, which was to achieve nor-
mal sodium levels or urine output >500 mL, or both (premise
1). The percentage of patients who experienced benefit rose
to 95% when the criteria reflected a relative increase in se-
rum sodium of ≥4 mEq/L and urine output of 300 mL.
Changes in sodium levels and urine output produced were
accompanied by weight loss, a measurement directly associ-
ated with reduced oedema. Regarding improvement in so-
dium concentration, increased levels have been previously
demonstrated in trials and in small clinical studies with HF
patients.12,24–27 Therefore, our results contribute valuable
data to the body of knowledge, by showing the contribution
of tolvaptan also in other clinical aspects, namely increasing
urine output and reducing oedema, two key factors in the
clinical management of congestive symptoms and which
indicate response to treatment and short-term prognosis.
According to our data, in practice tolvaptan is initiated at
low doses, and gradual dose increments are required to
achieve normal sodium levels. This is usually reached in ap-
proximately 4 days, although some patients never reach this
target. Tolvaptan is generally administered for a period of
2–10 days: treatment duration is important, as demonstrated
by our observation of an association between duration and
increased sodium levels (criteria for premise of benefit no.
4). A small number of patients received treatment for over
30 days, the limit stated by the Food and Drug Administration
for this drug.28 However, this warning was not issued by the
European Medicines Agency.29 Treatment may be extended
for clinical reasons, and close monitoring of liver function is
recommended. No liver complications were reported during
the treatment period in any of the patients in the registry.
It is interesting to note that outcomes varied widely, as al-
most half of the patients did not achieve normal sodium
levels during the treatment period. This figure is consistent
with those of clinical trials of tolvaptan, in which 10–50% of
patients did not respond,11,12 but the reasons for this varia-
tion remain unclear. It has been previously reported that pa-
tient status at the beginning of treatment impacts on efficacy,
and patients with severe hyponatraemia achieve better out-
comes.13,14,26,27 Circulating vasopressin levels can also affect
outcome, as can the degree of success experienced with fluid
restrictions.30 Moreover, possible differences in the ap-
proaches taken in the different hospitals (e.g. doses, treat-
ment duration and concomitant management) may have
been under-reported, impacting on our analysis. In contrast
to SIADH, in which hyponatraemia depends exclusively on
antidiuretic hormone (ADH) action, the mechanism of
hyponatraemia in HF is mixed. In HF, not only ADH, but also
the renin angiotensin system and the adrenergic nervous sys-
tem play a part, so response to blocking this hormone may be
more heterogeneous. Finally, it has also been suggested that
differences in response reflect V2 receptor mutations which
affect tolvaptan pharmacokinetics (e.g. vasopressin-
independent SIADH).31
One of the objectives of this study was to determine the
factors associated with achieving the different premises of
benefit. Glomerular filtration at the end of treatment was re-
lated with an improvement in sodium levels and urine out-
put, although overall increases in glomerular filtration did
not reach statistical significance. Improved final glomerular
filtration rate and reduced blood potassium were favourably
associated with achieving normal sodium levels in the 2 ben-
efit premises which included the criterion [Na+] ≥ 135 mEq/L.
The significance of this association is difficult to ascertain, but
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it seems that patients who benefit more from the treatment,
in terms of sodium levels and urine output, also tend to expe-
rience improvements in renal function.
Treatment duration (>2 days) had a strong and significant
effect on achieving a relative increase of 4 mEq/L in serum
sodium, so perhaps tolvaptan should be administered for
more than 2 days before it is considered useless, and the
dose should also be adjusted during the early days of admin-
istration, as recommended for other indications such as
SIADH. Patient age (>65 years) has previously been reported
as a factor impacting negatively on the efficacy of tolvaptan
in terms of 24 h urine volume,32 but our analysis revealed
no relationship between age and urine output. The mean
age of our patients was 67 years, but we included patients
aged from 18 to 95 years, so the age range was wide enough
for assessment. No significant relationships between baseline
patient variables were found that could be predictive of
treatment efficacy.
Hyponatraemia occurring in advanced HF has been consid-
ered for many years as a poor prognostic factor in HF.19,20
Recovery is associated with an improved prognosis, but the
outlook is generally very poor in these patients, in view of
their advanced disease. Tolvaptan may be useful as a decon-
gestive aquaretic, but improving hyponatraemia may also im-
prove the short-term prognosis for morbidity and mortality in
these patients.33,34
The limitations of this study are those inherent to retro-
spective studies based on multicentre registries, in which
only limited data on patient management are available,
and in this study, no standardized treatment strategy was
agreed among the hospitals. However, this database was
specifically designed for the purposes of this study, and
the data quality was ensured with appropriate periodical
controls. Only clinical and laboratory data used in routine
practice were recorded, and no extra sampling or determi-
nations of possible biomarkers was not planned, as fast
therapeutic decision-making regarding treatment in these
patients is crucial. Comparison with patients not refractory
to diuretics was not planned. This study is valuable because
it examines a national patient series, with the participation
of different hospitals which followed their own clinical
treatment protocols and included real patients with a wide
range of baseline situations. Thus, the observation that
tolvaptan added to these patientsˈ treatment schedules
provided overall clinical benefits can be considered to be
robust. Nevertheless, various clinical and management
factors which may have affected the outcome were not
controlled, and these aspects should be explored in future
studies.
In conclusion, most patients hospitalized for decompen-
sated HF and hyponatraemia treated with tolvaptan added
to conventional diuretic treatment presented an increase in
serum sodium levels and/or urine output, and congestive
symptoms were improved. While more studies are needed
to examine in more depth the causes of lack of response
and predictive factors for response, tolvaptan may be
beneficial in patients for whom no alternative treatments
with proven efficacy are available. In view of the data from
the RCTs, the data presented here, and the general
impossibility of treating hyponatraemia in severe HF without
a vaptan, future updates of the European guidelines should
consider the utility of V2 antagonists in these patients.
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